Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
Purpose
This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrent). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's deoxyribonucleic acid and may kill tumor cells. Giving relatlimab and nivolumab may be safe, tolerable, and/or effective compared to standard of care lomustine in treating patients with recurrent glioblastoma.
Conditions
- Progressive Glioblastoma
- Recurrent Glioblastoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- Histologically-proven glioblastoma (World Health Organization [WHO] 2021 criteria)
- Progressive or recurrent disease per Response Assessment in Neuro-Oncology (RANO)
criteria
- No IDH mutation (IDH1 R132H negative by immunohistochemistry [IHC] or sequencing)
- Patients must be in first recurrence of glioblastoma following radiation therapy and
temozolomide
- No prior therapies except radiation, surgery, temozolomide, Tumor Treating Fields
(TTFields), and/or Gliadel wafers (placed during the first surgery at diagnosis of
glioblastoma multiforme [GBM]). Prior radiation therapy, TTFields, or placement of
Gliadel wafers must be completed at least 2 weeks prior to registration. Prior
temozolomide must be completed at least 3 weeks prior to registration
- No prior use of nivolumab or other anti-PD1 agents
- Patients must be neurologically stable off corticosteroids for at least 5 days prior
to registration
- Age: ≥ 18 years
- Karnofsky Performance Status: ≥ 60% (i.e. patient must be able to care for
themselves with occasional help from others)
- Absolute lymphocyte count (ALC): ≥ 1000/mm^3
- Absolute neutrophil count (ANC): ≥ 1500/mm^3
- Platelet count: ≥ 100,000/mm^3
- Hemoglobin: ≥ 9.0 g/dL
- Activated partial thromboplastin time (APTT) or partial thromboplastin time (PTT): ≤
1.5 x upper limit of normal (ULN)
- Total bilirubin: < 2.0 x ULN (Except for patients with Gilbert's syndrome, who must
have direct bilirubin < 2.0 x ULN)
- Aspartate aminotransferase (AST) / alanine aminotransferase (ALT): < 3.0 x ULN
- Calculated (calc.) creatinine clearance (CrCl): ≥ 50 mL/min
- Calculated by Cockcroft-Gault equation
- Not pregnant and not nursing, because this study involves an investigational agent
whose genotoxic, mutagenic and teratogenic effects on the developing fetus and
newborn are unknown and an agent that has known genotoxic, mutagenic and teratogenic
effects. Therefore, for women of childbearing potential only, a negative pregnancy
test done within 14 days prior to registration is required
- Patients with a prior or concurrent malignancy whose natural history or treatment
does not have the potential to interfere with the safety or efficacy assessment of
the investigational regimen are eligible for this trial
- No active brain metastases or leptomeningeal disease
- HIV: HIV-infected patients on effective anti-retroviral therapy with undetectable
viral load within 6 months prior to registration are eligible for this trial
- Hepatitis B: For patients with evidence of chronic hepatitis B virus (HBV)
infection, the HBV viral load must be undetectable on suppressive therapy, if
indicated
- Hepatitis C: Patients with a history of hepatitis C virus (HCV) infection must have
been treated and cured. For patients with HCV infection who are currently on
treatment, they are eligible if they have an undetectable HCV viral load
- No known medical condition causing an inability to swallow oral formulations of
agents
- No current symptomatic pulmonary disease
- No autoimmune disorders that require systemic treatment (except hyperthyroidism or
diabetes mellitus)
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Arm I (nivolumab, relatlimab) |
Patients receive nivolumab IV over 30 minutes followed by relatlimab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo surgery or biopsy, MRI, and blood sample collection throughout study. |
|
|
Active Comparator Arm II (lomustine) |
Patients receive lomustine PO on day 1 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo surgery or biopsy, MRI, and blood sample collection throughout study. |
|
Recruiting Locations
Jonesboro 4116834, Arkansas 4099753 72401
Auburn 5325223, California 5332921 95602
Duarte 5344147, California 5332921 91010
Dublin 5344157, California 5332921 94568
Site Public Contact
877-642-4691
Fremont 5350734, California 5332921 94538
Fresno 5350937, California 5332921 93720
Site Public Contact
833-574-2273
Irvine 5359777, California 5332921 92612
La Jolla 5363943, California 5332921 92093
Lancaster 5364940, California 5332921 93534
Long Beach 5367929, California 5332921 90813
Site Public Contact
877-467-3411
Los Angeles 5368361, California 5332921 90027
Los Angeles 5368361, California 5332921 90048
Site Public Contact
310-423-8965
Modesto 5373900, California 5332921 95356
Site Public Contact
877-642-4691
Modesto 5373900, California 5332921 95356
Oakland 5378538, California 5332921 94611
Orange 5379513, California 5332921 92868
Palo Alto 5380748, California 5332921 94301
Palo Alto 5380748, California 5332921 94304
Redwood City 5386834, California 5332921 94063
Site Public Contact
877-642-4691
Roseville 5388881, California 5332921 95661
Roseville 5388881, California 5332921 95661
Sacramento 5389489, California 5332921 95814
Sacramento 5389489, California 5332921 95816
Sacramento 5389489, California 5332921 95823
San Diego 5391811, California 5332921 92120
San Francisco 5391959, California 5332921 94115
San Francisco 5391959, California 5332921 94115
San Jose 5392171, California 5332921 95119
San Leandro 5392263, California 5332921 94577
San Rafael 5392567, California 5332921 94903
Santa Clara 5393015, California 5332921 95051
Santa Rosa 5393287, California 5332921 95403
South San Francisco 5397765, California 5332921 94080
Upland 5404915, California 5332921 91786
Vallejo 5405380, California 5332921 94589
Walnut Creek 5406990, California 5332921 94596
Walnut Creek 5406990, California 5332921 94598
Colorado Springs 5417598, Colorado 5417618 80909
Site Public Contact
719-365-2406
Colorado Springs 5417598, Colorado 5417618 80920
Site Public Contact
719-364-6700
Fort Collins 5577147, Colorado 5417618 80524
Site Public Contact
970-297-6150
Fort Collins 5577147, Colorado 5417618 80528
Greeley 5577592, Colorado 5417618 80631
Loveland 5579368, Colorado 5417618 80538
Site Public Contact
970-203-7083
Bridgeport 5282804, Connecticut 4831725 06606
Site Public Contact
860-972-4700
Hartford 4835797, Connecticut 4831725 06102
Site Public Contact
860-545-5363
New Haven 4839366, Connecticut 4831725 06520
Trumbull 4844459, Connecticut 4831725 06611
Millville 4143696, Delaware 4142224 19967
Newark 4143861, Delaware 4142224 19713
Newark 4143861, Delaware 4142224 19713
Rehoboth Beach 4144284, Delaware 4142224 19971
Washington D.C. 4140963, District of Columbia 4138106 20016
Aventura 4146429, Florida 4155751 33180
Site Public Contact
954-461-2180
Coral Gables 4151871, Florida 4155751 33146
Site Public Contact
305-243-2647
Coral Springs 4151909, Florida 4155751 33065
Site Public Contact
305-243-2647
Deerfield Beach 4153071, Florida 4155751 33442
Site Public Contact
305-243-2647
Doral 4153471, Florida 4155751 33166
Gainesville 4156404, Florida 4155751 32610
Hollywood 4158928, Florida 4155751 33021
Hollywood 4158928, Florida 4155751 33021
Site Public Contact
305-243-2647
Jacksonville 4160021, Florida 4155751 32207
Site Public Contact
904-202-7468
Jacksonville 4160021, Florida 4155751 32224-9980
Site Public Contact
855-776-0015
Miami 4164138, Florida 4155751 33136
Site Public Contact
305-243-2647
Miami 4164138, Florida 4155751 33176
Site Public Contact
305-243-2647
Orlando 4167147, Florida 4155751 32806
Plantation 4168782, Florida 4155751 33324
Site Public Contact
305-243-2647
Augusta 4180531, Georgia 4197000 30912
Honolulu 5856195, Hawaii 5855797 96819
Boise 5586437, Idaho 5596512 83706
Boise 5586437, Idaho 5596512 83712
Caldwell 5587698, Idaho 5596512 83605
Coeur d'Alene 5589173, Idaho 5596512 83814
Fruitland 5593708, Idaho 5596512 83619
Meridian 5600685, Idaho 5596512 83642
Nampa 5601933, Idaho 5596512 83687
Nampa 5601933, Idaho 5596512 83687
Post Falls 5604353, Idaho 5596512 83854
Sandpoint 5606401, Idaho 5596512 83864
Aurora 4883817, Illinois 4896861 60506
Barrington 4884116, Illinois 4896861 60010
Site Public Contact
847-842-4847
Bloomington 4885164, Illinois 4896861 61704
Canton 4831990, Illinois 4896861 61520
Carthage 4886716, Illinois 4896861 62321
Chicago 4887398, Illinois 4896861 60612
Chicago 4887398, Illinois 4896861 60612
Site Public Contact
312-355-3046
Chicago 4887398, Illinois 4896861 60657
Site Public Contact
773-296-5360
Crystal Lake 4889229, Illinois 4896861 60014
Decatur 4236895, Illinois 4896861 62526
Decatur 4236895, Illinois 4896861 62526
Dixon 4889959, Illinois 4896861 61021
Site Public Contact
815-285-7800
Downers Grove 4890119, Illinois 4896861 60515
Effingham 4237727, Illinois 4896861 62401
Elgin 4890864, Illinois 4896861 60123
Site Public Contact
847-429-2907
Eureka 4891310, Illinois 4896861 61530
Evanston 4891382, Illinois 4896861 60201
Site Public Contact
847-570-2109
Galesburg 4893392, Illinois 4896861 61401
Glenview 4893886, Illinois 4896861 60026
Site Public Contact
847-570-2109
Hazel Crest 4895416, Illinois 4896861 60429
Site Public Contact
708-799-9995
Kewanee 4898433, Illinois 4896861 61443
Libertyville 4899739, Illinois 4896861 60048
Libertyville 4899739, Illinois 4896861 60048
Macomb 4900817, Illinois 4896861 61455
O'Fallon 4245926, Illinois 4896861 62269
O'Fallon 4245926, Illinois 4896861 62269
Oak Lawn 4904365, Illinois 4896861 60453-2699
Site Public Contact
800-323-8622
Oak Lawn 4904365, Illinois 4896861 60453
Ottawa 4905006, Illinois 4896861 61350
Palos Heights 4905259, Illinois 4896861 60463
Park Ridge 4905367, Illinois 4896861 60068
Site Public Contact
847-384-3621
Pekin 4905599, Illinois 4896861 61554
Peoria 4905687, Illinois 4896861 61615
Peru 4905770, Illinois 4896861 61354
Princeton 4906818, Illinois 4896861 61356
Shiloh 4249910, Illinois 4896861 62269
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
217-545-7929
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
800-444-7541
Springfield 4250542, Illinois 4896861 62781
Washington 4915545, Illinois 4896861 61571
Indianapolis 4259418, Indiana 4921868 46237
Site Public Contact
317-528-7060
Ames 4846834, Iowa 4862182 50010
Site Public Contact
515-956-4132
Ames 4846834, Iowa 4862182 50010
Ankeny 4846960, Iowa 4862182 50023
Site Public Contact
515-241-3305
Bettendorf 4848489, Iowa 4862182 52722
Boone 4849051, Iowa 4862182 50036
Site Public Contact
515-956-4132
Carroll 4850478, Iowa 4862182 51401
Cedar Rapids 4850751, Iowa 4862182 52403
Site Public Contact
319-365-4673
Cedar Rapids 4850751, Iowa 4862182 52403
Site Public Contact
319-363-2690
Clive 4852065, Iowa 4862182 50325
Site Public Contact
515-241-3305
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-6727
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-3305
Des Moines 4853828, Iowa 4862182 50314
Site Public Contact
515-282-2200
Des Moines 4853828, Iowa 4862182 50314
Site Public Contact
515-241-3305
Fort Dodge 4857486, Iowa 4862182 50501
Site Public Contact
515-956-4132
Fort Dodge 4857486, Iowa 4862182 50501
Iowa City 4862034, Iowa 4862182 52242
Site Public Contact
800-237-1225
Jefferson 4862482, Iowa 4862182 50129
Site Public Contact
515-956-4132
Marshalltown 4866371, Iowa 4862182 50158
Site Public Contact
515-956-4132
Waukee 4880981, Iowa 4862182 50263
Site Public Contact
515-241-3305
Kansas City 4273837, Kansas 4273857 66160
Overland Park 4276873, Kansas 4273857 66210
Overland Park 4276873, Kansas 4273857 66211
Westwood 4281639, Kansas 4273857 66205
Lexington 4297983, Kentucky 6254925 40536
Site Public Contact
859-257-3379
Louisville 4299276, Kentucky 6254925 40202
Site Public Contact
502-562-3429
Brewer 4959233, Maine 4971068 04412
Site Public Contact
800-987-3005
South Portland 4979244, Maine 4971068 04106
Baltimore 4347778, Maryland 4361885 21287
Boston 4930956, Massachusetts 6254926 02111
Ann Arbor 4984247, Michigan 5001836 48106
Ann Arbor 4984247, Michigan 5001836 48109
Brighton 4986994, Michigan 5001836 48114
Brighton 4986994, Michigan 5001836 48116
Site Public Contact
800-865-1125
Canton 4987990, Michigan 5001836 48188
Chelsea 4988628, Michigan 5001836 48118
Escanaba 4992232, Michigan 5001836 49829
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48503
Lansing 4998830, Michigan 5001836 48912
Livonia 4999837, Michigan 5001836 48154
Ypsilanti 5015688, Michigan 5001836 48197
Bemidji 5017822, Minnesota 5037779 56601
Brainerd 5019116, Minnesota 5037779 56401
Deer River 5024099, Minnesota 5037779 56636
Duluth 5024719, Minnesota 5037779 55805
Edina 5025264, Minnesota 5037779 55435
Hibbing 5030005, Minnesota 5037779 55746
Site Public Contact
218-786-3308
Minneapolis 5037649, Minnesota 5037779 55407
Minneapolis 5037649, Minnesota 5037779 55415
Sandstone 5045908, Minnesota 5037779 55072
Virginia 5051468, Minnesota 5037779 55792
Columbus 4422442, Mississippi 4436296 39705
Grenada 4428539, Mississippi 4436296 38901
New Albany 4438121, Mississippi 4436296 38652
Oxford 4440076, Mississippi 4436296 38655
Southhaven 4446702, Mississippi 4436296 38671
Cape Girardeau 4379966, Missouri 4398678 63703
City of Saint Peters 4407237, Missouri 4398678 63376
Creve Coeur 4382837, Missouri 4398678 63141
St Louis 4407066, Missouri 4398678 63110
St Louis 4407066, Missouri 4398678 63129
St Louis 4407066, Missouri 4398678 63136
Anaconda 5637146, Montana 5667009 59711
Billings 5640350, Montana 5667009 59101
Bozeman 5641727, Montana 5667009 59715
Great Falls 5655240, Montana 5667009 59405
Kalispell 5660340, Montana 5667009 59901
Missoula 5666639, Montana 5667009 59804
Bellevue 5063805, Nebraska 5073708 68123
Omaha 5074472, Nebraska 5073708 68118
Site Public Contact
402-559-5600
Omaha 5074472, Nebraska 5073708 68198
Reno 5511077, Nevada 5509151 89502
Hackensack 5098706, New Jersey 5101760 07601
Site Public Contact
551-996-2897
Morristown 5101427, New Jersey 5101760 07960
Site Public Contact
973-971-5900
Neptune City 5101687, New Jersey 5101760 07753
Site Public Contact
732-776-4240
Sewell 4504048, New Jersey 5101760 08080
Summit 5105127, New Jersey 5101760 07902
Site Public Contact
908-522-2043
Albuquerque 5454711, New Mexico 5481136 87106
Albuquerque 5454711, New Mexico 5481136 87110
Rio Rancho 5487811, New Mexico 5481136 87124
Bay Shore 5108169, New York 5128638 11706
Site Public Contact
516-734-8896
Brooklyn 5110302, New York 5128638 11220
Buffalo 5110629, New York 5128638 14263
Glens Falls 5118693, New York 5128638 12801
Site Public Contact
518-926-6700
Lake Success 5123853, New York 5128638 11042
Site Public Contact
516-734-8896
Mineola 5127134, New York 5128638 11501
New York 5128581, New York 5128638 10016
New York 5128581, New York 5128638 10032
Rochester 5134086, New York 5128638 14642
Site Public Contact
585-275-5830
The Bronx 5110266, New York 5128638 10461
Pinehurst 4485272, North Carolina 4482348 28374
Bismarck 5688025, North Dakota 5690763 58501
Fargo 5059163, North Dakota 5690763 58103
Fargo 5059163, North Dakota 5690763 58122
Fargo 5059163, North Dakota 5690763 58122
Centerville 4508204, Ohio 5165418 45459
Cincinnati 4508722, Ohio 5165418 45219
Cincinnati 4508722, Ohio 5165418 45220
Columbus 4509177, Ohio 5165418 43210
Columbus 4509177, Ohio 5165418 43214
Dayton 4509884, Ohio 5165418 45409
Dayton 4509884, Ohio 5165418 45409
Site Public Contact
937-276-8320
Dayton 4509884, Ohio 5165418 45415
Franklin 4512203, Ohio 5165418 45005-1066
Greenville 5156493, Ohio 5165418 45331
Site Public Contact
937-569-7515
Troy 5174358, Ohio 5165418 45373
West Chester 4520522, Ohio 5165418 45069
Oklahoma City 4544349, Oklahoma 4544379 73104
Gresham 5729485, Oregon 5744337 97030
Site Public Contact
503-413-2150
Ontario 5744166, Oregon 5744337 97914
Portland 5746545, Oregon 5744337 97210
Portland 5746545, Oregon 5744337 97213
Portland 5746545, Oregon 5744337 97225
Portland 5746545, Oregon 5744337 97239
Tualatin 5757506, Oregon 5744337 97062
Site Public Contact
503-413-1742
Allentown 5178127, Pennsylvania 6254927 18103
Bethlehem 5180225, Pennsylvania 6254927 18017
East Stroudsburg 5188075, Pennsylvania 6254927 18301
Erie 5188843, Pennsylvania 6254927 16544
Site Public Contact
814-452-5000
Jefferson Hills 5195297, Pennsylvania 6254927 15025
Monroeville 5201734, Pennsylvania 6254927 15146
Site Public Contact
412-858-7746
Philadelphia 4560349, Pennsylvania 6254927 19107
Pittsburgh 5206379, Pennsylvania 6254927 15212
Site Public Contact
877-284-2000
Pittsburgh 5206379, Pennsylvania 6254927 15224
Site Public Contact
412-578-5000
Pittsburgh 5206379, Pennsylvania 6254927 15232
Site Public Contact
412-647-8073
Wexford 5219062, Pennsylvania 6254927 15090
Charleston 4574324, South Carolina 4597040 29425
Sioux Falls 5231851, South Dakota 5769223 57104
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Collierville 4614748, Tennessee 4662168 38017
Memphis 4641239, Tennessee 4662168 38120
Nashville 4644585, Tennessee 4662168 37232
Site Public Contact
800-811-8480
Salt Lake City 5780993, Utah 5549030 84112
Burlington 5234372, Vermont 5242283 05401
Burlington 5234372, Vermont 5242283 05405
Fairfax 4758023, Virginia 6254928 22031
Mechanicsville 4772566, Virginia 6254928 23116
Midlothian 4772943, Virginia 6254928 23114
Richmond 4781708, Virginia 6254928 23223
Richmond 4781708, Virginia 6254928 23226
Richmond 4781708, Virginia 6254928 23298
Vancouver 5814616, Washington 5815135 98684
Vancouver 5814616, Washington 5815135 98686
Site Public Contact
503-413-2150
Morgantown 4815352, West Virginia 4826850 26506
Parkersburg 4817641, West Virginia 4826850 26101
Wheeling 5280854, West Virginia 4826850 26003
Site Public Contact
304-243-6442
Ashland 5244247, Wisconsin 5279468 54806
Burlington 5247214, Wisconsin 5279468 53105
Cudahy 5249871, Wisconsin 5279468 53110
Eau Claire 5251436, Wisconsin 5279468 54701
Germantown 5254218, Wisconsin 5279468 53022
Grafton 5254739, Wisconsin 5279468 53024
Green Bay 5254962, Wisconsin 5279468 54301
Green Bay 5254962, Wisconsin 5279468 54303
Green Bay 5254962, Wisconsin 5279468 54311
Janesville 5257754, Wisconsin 5279468 53548
Kenosha 5258393, Wisconsin 5279468 53142
Madison 5261457, Wisconsin 5279468 53718
Madison 5261457, Wisconsin 5279468 53792
Marinette 5261852, Wisconsin 5279468 54143
Marshfield 5261969, Wisconsin 5279468 54449
Milwaukee 5263045, Wisconsin 5279468 53209
Milwaukee 5263045, Wisconsin 5279468 53215
Milwaukee 5263045, Wisconsin 5279468 53233
Mukwonago 5263965, Wisconsin 5279468 53149
Oconomowoc 5265499, Wisconsin 5279468 53066
Site Public Contact
262-928-7878
Oconto Falls 5265522, Wisconsin 5279468 54154
Oshkosh 5265838, Wisconsin 5279468 54904
Racine 5268249, Wisconsin 5279468 53406
Sheboygan 5272893, Wisconsin 5279468 53081
Sheboygan 5272893, Wisconsin 5279468 53081
Sheboygan 5272893, Wisconsin 5279468 53081
Stevens Point 5274644, Wisconsin 5279468 54482
Sturgeon Bay 5274867, Wisconsin 5279468 54235-1495
Summit, Wisconsin 5279468 53066
Two Rivers 5276609, Wisconsin 5279468 54241
Waukesha 5278052, Wisconsin 5279468 53188
Site Public Contact
262-928-7632
Waukesha 5278052, Wisconsin 5279468 53188
Wauwatosa 5278159, Wisconsin 5279468 53226
West Allis 5278420, Wisconsin 5279468 53227
Weston 5278693, Wisconsin 5279468 54476
More Details
- NCT ID
- NCT06325683
- Status
- Recruiting
- Sponsor
- National Cancer Institute (NCI)
Detailed Description
PRIMARY OBJECTIVE: I. To compare the restricted mean survival time (RMST) for overall survival (OS) between patients receiving the combination of relatlimab (BMS-986016) and nivolumab versus patients receiving standard of care chloroethylcyclohexylnitrosourea (CCNU) (lomustine). SECONDARY OBJECTIVES: I. To compare the 12-month OS rates between patients receiving the combination of relatlimab (BMS-986016) and nivolumab versus patients receiving standard of care CCNU (lomustine). II. To compare the restricted mean survival times for progression-free survival (PFS) between patients receiving the combination of relatlimab (BMS-986016) and nivolumab versus patients receiving standard of care CCNU (lomustine). III. To compare the radiographic response rate between patients receiving the combination of relatlimab (BMS-986016) and nivolumab versus patients receiving standard of care CCNU (lomustine). IV. To compare the safety/adverse event rate between patients receiving the combination of relatlimab (BMS-986016) and nivolumab versus patients receiving standard of care CCNU (lomustine). OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive nivolumab intravenously (IV) over 30 minutes followed by relatlimab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo surgery or biopsy, magnetic resonance imaging (MRI), and blood sample collection throughout study. ARM II: Patients receive lomustine orally (PO) on day 1 of each cycle. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo surgery or biopsy, MRI, and blood sample collection throughout study. After completion of study treatment, patients are followed up every 6 months for up to 5 years from time of randomization.